|1.||Ibáñez, Lourdes: 17 articles (01/2015 - 06/2002)|
|2.||Chaudry, Irshad H: 13 articles (08/2008 - 01/2002)|
|3.||de Zegher, Francis: 12 articles (01/2015 - 01/2003)|
|4.||Bland, Kirby I: 9 articles (08/2008 - 01/2002)|
|5.||Choudhry, Mashkoor A: 8 articles (08/2008 - 07/2005)|
|6.||Crawford, E David: 5 articles (03/2012 - 09/2002)|
|7.||De Zegher, Francis: 5 articles (12/2010 - 06/2002)|
|8.||Schwacha, Martin G: 5 articles (08/2008 - 01/2002)|
|9.||Hsieh, Ya-Ching: 5 articles (02/2007 - 07/2005)|
|10.||Yu, Huang-Ping: 5 articles (02/2007 - 07/2005)|
|1.||Prostatic Neoplasms (Prostate Cancer)
09/01/2000 - "Parameters of liver function, serum GOT and GPT levels, which were normal at the baseline, became abnormal in 30.0% and 35.3%, respectively, of patients in Group II. These figures were significantly higher than the corresponding figures of 6.3% and 12.5%, respectively, in Group I. When the degree of change in each of these parameters was analyzed, both GOT and GPT levels showed a significantly greater increase in Group II than in Group I. These results indicate that attention must be paid to changes in liver function during the administration of flutamide in patients with prostate cancer even if their baseline liver function is normal. "
06/01/1986 - "Since uninterrupted administration of the antiandrogen is of the outmost importance for the successful therapy of prostatic cancer, the availability of a compound such as flutamide that has no side effect other than those due to hypoandrogenicity should greatly facilitate compliance by the patients and the success of the treatment."
06/01/2012 - "Flutamide, an antiandrogen drug, is widely used for the treatment of prostate cancer. "
07/01/2009 - "Flutamide, an antiandrogen drug, is widely used for the treatment of prostate cancer. "
11/01/2003 - "The administration of low-dose flutamide (125 mg) was clinically effective in treating PSA recurrence after definitive treatments for prostate cancer, and was well tolerated. "
04/01/2009 - "Flutamide is very effective for hirsutism treatment; however, adverse effects are very frequent and associated with low long-term compliance."
08/01/1996 - "Treatment with the antiandrogen flutamide resulted in a particularly rapid and marked decrease in the hirsutism score, which decreased from 17.48 +/- 5.35 to 5.07 +/- 2.89 after 6 months. "
09/01/1990 - "Treatment with the antiandrogen flutamide (250 mg twice daily) and an oral contraceptive (Ortho 1/35) resulted in a particularly rapid and marked decrease in the total hirsutism score, which reached the normal range at 7 months. "
03/01/1999 - "Hirsutism greatly improved during flutamide therapy, and the hirsutism score significantly decreased at month 3 and 6 from a mean (+/-SD) of 17.19+/-4.55 to 10.75+/-3.84 (p<0.001) and 17.19+/-4.55 to 5.91+/-2.53 (p<0.001), respectively. "
01/01/2001 - "To evaluate the safety and efficacy of a low dose of flutamide (125 mg/day) in maintaining the clinical results already obtained using a higher dose (250 mg/day), in women suffering from hirsutism. "
11/01/1979 - "Flutamide seems to be a safe antiandrogen, which is effective in the management of previously untreated patients with advanced prostatic carcinoma."
05/01/1976 - "Flutamide is a new nonsteroidal antiandrogen useful in the treatment of prostatic carcinoma. "
10/01/1991 - "Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma. "
03/01/2004 - "In consideration of the clinical indication of flutamide for advanced prostatic carcinoma and based upon reports of minimal flutamide-related adverse clinical responses, the findings of this study pose no concern for human risk assessment."
01/01/2011 - "All men received flutamide as treatment of advanced prostate carcinoma and they developed hepatotoxicity without ALF, and three months after withdrawal of the drug, they recovered completely. "
12/01/2014 - "Although additional study is considered necessary to determine the daily dosage of flutamide, the anti-tumor effects obtained from this study indicated that 375 mg/day is appropriate as a daily dosage, and 250 mg/day can also be considered when concern exists regarding the occurrence of complications or the development of ADRs, including liver function disorders. "
01/03/2014 - "The chemical name of 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide is usually called as Flutamide (In the present study it is abbreviated as FLT) and is an important and efficacious drug in the treatment of anti-cancer resistant. "
01/03/2014 - "Spectral and structural studies of the anti-cancer drug Flutamide by density functional theoretical method."
03/01/2012 - "Mechanistic study on liver tumor promoting effects of flutamide in rats."
02/01/1987 - "Seven patients left the study because of progression of cancer and two because of the side effects of Flutamide. "
|5.||Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
04/01/2013 - "The long-term effects and tolerability of flutamide (Flu) on the menstrual cycle and the ovulatory function of hyperandrogenic women with or without polycystic ovary syndrome (PCOS) were investigated. "
04/01/2013 - "Ovulatory effects of flutamide in the polycystic ovary syndrome."
09/01/2004 - "In conclusion, low-dose flutamide is herewith identified as a pivotal component within a first contraceptive combination therapy that has been shown to attenuate the hypoadiponectinemia, ovarian vascular hyperresistance, lean mass deficit, and central adiposity of young women with polycystic ovary syndrome. "
07/01/2003 - "Fourteen obese women with polycystic ovary syndrome (PCOS) on a hypocaloric diet were randomly assigned to treatment groups (open-labeled design), receiving either placebo (no.=7) or the antiandrogen flutamide (no.=7) for 6 months. "
06/01/2002 - "To evaluate whether, by blocking androgen action, flutamide can decrease and normalize vascular resistance in the uterine artery in patients with polycystic ovary syndrome (PCOS). "
|2.||Gonadotropin-Releasing Hormone (GnRH)
|8.||Androgen Receptors (Androgen Receptor)
|10.||Androgen Antagonists (Antiandrogens)
|5.||Prostatectomy (Retropubic Prostatectomy)